Veru Inc. (VERU)
NASDAQ: VERU · Real-Time Price · USD
2.580
-0.080 (-3.01%)
At close: Feb 27, 2026, 4:00 PM EST
2.630
+0.050 (1.94%)
After-hours: Feb 27, 2026, 6:45 PM EST
Veru Inc. Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
20
Market Cap
41.41M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | - | - | - |
| Sep 30, 2024 | - | - | - |
| Sep 30, 2023 | 16.30M | -23.06M | -58.59% |
| Sep 30, 2022 | 39.35M | -21.91M | -35.76% |
| Sep 30, 2021 | 61.26M | 18.67M | 43.83% |
| Sep 30, 2020 | 42.59M | 10.79M | 33.92% |
| Sep 30, 2019 | 31.80M | 15.94M | 100.47% |
| Sep 30, 2018 | 15.86M | 2.21M | 16.18% |
| Sep 30, 2017 | 13.66M | -8.47M | -38.29% |
| Sep 30, 2016 | 22.13M | -10.48M | -32.13% |
| Sep 30, 2015 | 32.60M | 8.11M | 33.13% |
| Sep 30, 2014 | 24.49M | -6.97M | -22.15% |
| Sep 30, 2013 | 31.46M | -3.58M | -10.21% |
| Sep 30, 2012 | 35.03M | 16.47M | 88.71% |
| Sep 30, 2011 | 18.57M | -3.66M | -16.46% |
| Sep 30, 2010 | 22.22M | -5.32M | -19.32% |
| Sep 30, 2009 | 27.54M | 1.91M | 7.45% |
| Sep 30, 2008 | 25.63M | 6.31M | 32.68% |
| Sep 30, 2007 | 19.32M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Xilio Therapeutics | 31.80M |
| NovaBay Pharmaceuticals | 10.30M |
| Apollomics | 6.93M |
| CervoMed | 6.16M |
| Aligos Therapeutics | 2.65M |
| Lisata Therapeutics | 1.07M |
| Impact BioMedical | 25.00K |
VERU News
- 16 days ago - Veru Inc. (VERU) Q1 2026 Earnings Call Transcript - Seeking Alpha
- 24 days ago - Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th - GlobeNewsWire
- 2 months ago - Veru Inc. (VERU) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress - GlobeNewsWire
- 2 months ago - Veru to Report Fiscal Year 2025 Financial Results on December 17th - GlobeNewsWire
- 4 months ago - Veru to Present Two Abstracts at ObesityWeek 2025 - GlobeNewsWire
- 4 months ago - Veru Announces Proposed Public Offering - GlobeNewsWire
- 5 months ago - Veru Announces Successful FDA Meeting Providing Regulatory Clarity for Enobosarm for Muscle Preservation in Combination with GLP-1 RA for Greater Weight Loss in the Treatment of Obesity - GlobeNewsWire